Blood Immune Cells After Bone Marrow Transplant for Leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that is not secondary to another condition
- Your leukemia is in complete remission (no signs of cancer) before transplant
- You are able to perform daily activities with minimal help (Karnofsky score 80% or higher)
- You will receive stem cells from your own blood (peripheral blood stem cells), not bone marrow
- You have never had a stem cell transplant before
- Your cancer is controlled and not actively progressing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at changes in your immune cells (T cells) in people with acute myeloid leukemia (AML) who are scheduled for a donor stem cell transplant. It may help doctors better understand how the immune system responds during and after transplant.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This study looks at natural killer (NK) cells, which are part of the immune system, in the blood of people who have had a stem cell transplant for acute leukemia or myelodysplasia. It aims to understand how these cells change after transplant and potentially predict outcomes.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Hear when a new Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.